Tsunoda T - Search Results

1

Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.

Tada Y, Yokomizo A, Shiota M, Tsunoda T, Plass C, Naito S. Tada Y, et al. Among authors: tsunoda t. Int J Oncol. 2011 Sep;39(3):727-33. doi: 10.3892/ijo.2011.1049. Epub 2011 May 23. Int J Oncol. 2011. PMID: 21617853

2

A novel mechanism of nuclear factor kappaB activation through the binding between inhibitor of nuclear factor-kappaBalpha and the processed NH(2)-terminal region of Mig-6.

Tsunoda T, Inokuchi J, Baba I, Okumura K, Naito S, Sasazuki T, Shirasawa S. Tsunoda T, et al. Cancer Res. 2002 Oct 15;62(20):5668-71. Cancer Res. 2002. PMID: 12384522

3

Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines.

Tsunoda T, Koga H, Yokomizo A, Tatsugami K, Eto M, Inokuchi J, Hirata A, Masuda K, Okumura K, Naito S. Tsunoda T, et al. Oncogene. 2005 Feb 17;24(8):1396-402. doi: 10.1038/sj.onc.1208313. Oncogene. 2005. PMID: 15608674

4

A laparoscopic radical prostatectomy assisted by the "ZEUS" robotic system: an initial case report.

Eto M, Yokomizo A, Koga H, Tsunoda T, Kakeji Y, Hashizume M, Naito S. Eto M, et al. Among authors: tsunoda t. Fukuoka Igaku Zasshi. 2005 Feb;96(2):58-62. Fukuoka Igaku Zasshi. 2005. PMID: 15852664 Free article.

5

Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.

Yokomizo A, Yamamoto K, Kinukawa N, Tsunoda T, Koga H, Naito S. Yokomizo A, et al. Among authors: tsunoda t. Int J Urol. 2007 Jun;14(6):500-4. doi: 10.1111/j.1442-2042.2007.01769.x. Int J Urol. 2007. PMID: 17593093

6

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

Furusato B, Tsunoda T, Shaheduzzaman S, Nau ME, Vahey M, Petrovics G, McLeod DG, Naito S, Shirasawa S, Srivastava S, Sesterhenn IA. Furusato B, et al. Among authors: tsunoda t. Urology. 2010 Apr;75(4):768-72. doi: 10.1016/j.urology.2009.10.026. Epub 2009 Dec 29. Urology. 2010. PMID: 20035976

7

Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin.

Shiota M, Tsunoda T, Song Y, Yokomizo A, Tada Y, Oda Y, Naito S. Shiota M, et al. Among authors: tsunoda t. BJU Int. 2011 Apr;107(7):1148-53. doi: 10.1111/j.1464-410X.2010.09535.x. Epub 2010 Aug 19. BJU Int. 2011. PMID: 20726978

8

Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells.

Terado T, Kim CJ, Ushio A, Minami K, Tambe Y, Kageyama S, Kawauchi A, Tsunoda T, Shirasawa S, Tanaka H, Inoue H. Terado T, et al. Among authors: tsunoda t. Int J Oncol. 2022 Sep;61(3):108. doi: 10.3892/ijo.2022.5398. Epub 2022 Jul 27. Int J Oncol. 2022. PMID: 35894141 Free PMC article.

9

Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.

Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T, Shirasawa S. Tsunoda T, et al. Anticancer Res. 2011 Jul;31(7):2453-9. Anticancer Res. 2011. PMID: 21873159

10

KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.

Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S. Yoshida Y, et al. Among authors: tsunoda t. Anticancer Res. 2011 Jul;31(7):2535-9. Anticancer Res. 2011. PMID: 21873171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,191 results

Search Page

Filters